NASDAQ:TRVN - Trevena Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $5.00
  • Forecasted Upside: 300.00 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.11 (-8.09%)

This chart shows the closing price for TRVN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Trevena Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TRVN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TRVN

Analyst Price Target is $5.00
▲ +300.00% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Trevena in the last 3 months. The average price target is $5.00, with a high forecast of $5.00 and a low forecast of $5.00. The average price target represents a 300.00% upside from the last price of $1.25.

This chart shows the closing price for TRVN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in Trevena. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/15/2021OppenheimerInitiated CoverageMarket PerformMedium
9/14/2020GuggenheimInitiated CoverageBuy$5.00High
8/27/2020Cantor FitzgeraldInitiated CoverageOverweight$5.00High
8/11/2020HC WainwrightBoost Price TargetBuy$4.00 ➝ $5.00Low
6/16/2020HC WainwrightReiterated RatingBuyHigh
3/13/2020HC WainwrightReiterated RatingBuy$3.50High
11/5/2019HC WainwrightReiterated RatingBuy$3.50High
6/24/2019HC WainwrightSet Price TargetBuy$4.00Low
5/31/2019HC WainwrightInitiated CoverageNeutral ➝ Buy$3.50High
3/14/2019HC WainwrightReiterated RatingHold$1.25High
11/5/2018HC WainwrightDowngradeBuy ➝ Neutral$3.00 ➝ $0.75High
10/12/2018HC WainwrightLower Price TargetBuy$7.00 ➝ $3.00Medium
10/12/2018JMP SecuritiesBoost Price TargetOutperform$4.00 ➝ $15.00High
10/12/2018Needham & Company LLCDowngradeBuy ➝ HoldHigh
10/10/2018Jefferies Financial GroupDowngradeBuy ➝ Hold$10.00 ➝ $1.00High
8/13/2018HC WainwrightReiterated RatingBuy$7.00Low
5/7/2018CowenReiterated RatingBuy$10.00High
5/3/2018OppenheimerSet Price TargetBuy$5.00High
3/22/2018OppenheimerReiterated RatingBuyLow
3/12/2018OppenheimerSet Price TargetBuy$5.00Low
3/8/2018HC WainwrightBoost Price TargetBuy$7.00High
11/13/2017OppenheimerReiterated RatingBuy$5.00N/A
11/8/2017HC WainwrightReiterated RatingBuy$5.00N/A
11/8/2017Needham & Company LLCLower Price TargetBuy$9.00 ➝ $7.00N/A
10/16/2017BarclaysDowngradeOverweight ➝ Equal Weight$15.00 ➝ $2.50N/A
10/12/2017OppenheimerSet Price TargetBuy$5.00N/A
10/12/2017HC WainwrightLower Price TargetBuy ➝ Buy$8.00 ➝ $7.00N/A
8/4/2017CowenReiterated RatingBuy$10.00Medium
8/3/2017OppenheimerSet Price TargetBuy$8.00Medium
5/15/2017Needham & Company LLCBoost Price TargetBuy$9.00 ➝ $11.00Low
5/8/2017HC WainwrightReiterated RatingBuyLow
5/6/2017Roth CapitalSet Price TargetBuy$9.00Medium
5/5/2017Needham & Company LLCReiterated RatingBuy ➝ Buy$11.00 ➝ $9.00Low
5/4/2017OppenheimerSet Price TargetBuy$10.00Medium
4/17/2017AegisReiterated RatingBuy$14.00Low
4/5/2017Needham & Company LLCReiterated RatingBuy$11.00High
3/22/2017OppenheimerReiterated RatingBuyHigh
3/22/2017CowenReiterated RatingBuy$13.00Low
3/14/2017OppenheimerSet Price TargetBuy$10.00High
3/11/2017(FBRC)Set Price TargetBuy$8.00High
3/11/2017Needham & Company LLCReiterated RatingBuy$11.00N/A
2/23/2017OppenheimerReiterated RatingOutperform$13.00 ➝ $10.00N/A
2/23/2017HC WainwrightLower Price TargetBuy ➝ Buy$11.00 ➝ $8.00N/A
2/22/2017Roth CapitalSet Price TargetBuy$9.00N/A
2/22/2017AegisReiterated RatingBuy ➝ Positive$14.00N/A
2/22/2017(FBRC)Reiterated RatingOutperform ➝ Outperform$13.00 ➝ $8.00N/A
2/21/2017CowenReiterated RatingBuyN/A
2/16/2017Jefferies Financial GroupReiterated RatingBuy$11.00N/A
2/10/2017Jefferies Financial GroupReiterated RatingBuyN/A
2/2/2017LADENBURG THALM/SH SHInitiated CoverageBuy$15.00N/A
1/25/2017CowenReiterated RatingBuy$13.00N/A
1/9/2017HC WainwrightInitiated CoverageBuy$11.00N/A
1/5/2017OppenheimerInitiated CoverageOutperform$13.00N/A
1/4/2017Jefferies Financial GroupSet Price TargetBuy$11.00N/A
12/16/2016Needham & Company LLCReiterated RatingBuy$11.00N/A
12/1/2016WedbushReiterated RatingOutperform$16.00N/A
11/3/2016WedbushReiterated RatingOutperform$16.00N/A
10/25/2016Brean CapitalSet Price TargetBuy$14.00N/A
10/3/2016Brean CapitalSet Price TargetBuy$14.00N/A
9/15/2016Brean CapitalSet Price TargetBuy$14.00N/A
8/5/2016CowenReiterated RatingBuy$13.00N/A
8/5/2016Jefferies Financial GroupReiterated RatingBuyN/A
8/5/2016Brean CapitalReiterated RatingBuy$14.00N/A
(Data available from 8/5/2016 forward)
Trevena logo
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist that has completed Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
Read More

Today's Range

Now: $1.25
Low: $1.25
High: $1.38

50 Day Range

MA: $1.70
Low: $1.25
High: $2.20

52 Week Range

Now: $1.25
Low: $1.25
High: $3.68


2,236,396 shs

Average Volume

3,183,551 shs

Market Capitalization

$205.64 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Trevena?

The following Wall Street sell-side analysts have issued reports on Trevena in the last twelve months: Cantor Fitzgerald, Guggenheim, HC Wainwright, Oppenheimer Holdings Inc., and Zacks Investment Research.
View the latest analyst ratings for TRVN.

What is the current price target for Trevena?

3 Wall Street analysts have set twelve-month price targets for Trevena in the last year. Their average twelve-month price target is $5.00, suggesting a possible upside of 300.0%. Cantor Fitzgerald has the highest price target set, predicting TRVN will reach $5.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $5.00 for Trevena in the next year.
View the latest price targets for TRVN.

What is the current consensus analyst rating for Trevena?

Trevena currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TRVN will outperform the market and that investors should add to their positions of Trevena.
View the latest ratings for TRVN.

What other companies compete with Trevena?

How do I contact Trevena's investor relations team?

Trevena's physical mailing address is 955 Chesterbrook Boulevard Suite 110, Chesterbrook PA, 19087. The biopharmaceutical company's listed phone number is 610-354-8840 and its investor relations email address is [email protected] The official website for Trevena is